1. Background {#sec100525}
=============

Hepatitis C Virus (HCV) is an enveloped and single-stranded RNA virus, which belongs to the *Hepacivirus* genus. HCV infection mainly affects liver tissues and most infected people have a high risk to develop chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma (HCC) ([@A28473R1]). No vaccine is yet available to prevent HCV transmission. Several Direct Acting Antivirals (DAAs) drugs have been approved for HCV treatment ([@A28473R2], [@A28473R3]). However, pegylated interferon with ribavirin (PegIFN/RBV) is still the standard of care against HCV infection in most countries ([@A28473R4]).

Studies showed that about 10 - 15% of HCV infected patients recovered without receiving antiviral therapy. Gunduz F et al. reported that early responses of innate immunity such as induction of Type I interferons (IFNs) played a pivotal role in this process ([@A28473R5]). Type I IFNs act their antiviral effect by activating transcription of numerous IFN stimulated genes (ISGs), such as ADAR (RNA- specific adenosine deaminase) ([@A28473R6]), P56 ([@A28473R7]), OAS (oligoadenylate synthetases) ([@A28473R8]) and PKR (Protein Kinase R) ([@A28473R9]), which have antiviral properties against HCV. Virtually, all human cells are able to synthesize IFN-α/β in response to virus infection, while HCV primarily infects liver cells. Therefore, induction of IFNs in liver cells is especially important for controlling HCV infection.

Recent studies showed that *LRRFIP1* might act as a candidate that contributes to the production of IFN-β. *LRRFIP1*, with a full name of leucine-rich repeat (in Flightless I) interacting protein-1, is originally identified as a protein that plays a role during *Drosophila* embryogenesis and myogenesis ([@A28473R10], [@A28473R11]). The C-terminus of *LRRFIP1* has been described as having nucleic acid-binding activity, including the transactivating response region (TAR) hairpin of HIV ([@A28473R12], [@A28473R13]). Asen Bagashev reported that *LRRFIP1* induced type I IFNs in 3T3 cells in the presence of influenza virus ([@A28473R14]). Moreover, Yang et al. showed that *LRRFIP1* contributed to the production of IFN-β in macrophages induced by VSV (vesicular stomatitis virus) and *Listeria monocytogenes* ([@A28473R15]).

Several studies clarified that HCV RNA is a potent trigger of IFN induction in hepatocytes, leading to establishment of an antiviral status ([@A28473R16]). It is not clear whether *LRRFIP1* can induce innate immunity in hepatocytes and plays a role in controlling HCV infection.

2. Objectives {#sec100526}
=============

This study was performed to investigate the ability of *LRRFIP1* to regulate type I IFNs expression in hepatocytes.

3. Materials and Methods {#sec100535}
========================

3.1. Plasmids and Cells {#sec100527}
-----------------------

*LRRFIP1* was cloned from Huh7 cells cDNA by over-lapped polymerase chain reaction (PCR) using primers (Life Technologies, Shanghai, China) as follows (5' - 3'): *GCGAGCTAGCATGACCAGCCCCGCGGCCGCTCAAAG*, *CAGAACTCCCCTTGAGCCATCCAACTGTTG, CAACAGTTGGATGGCTCAAGGGGAGTT CTG* and *GGCAGTCTAGATTAGGACATGGTACAGTCTTCTTTG*. PCR product was sequenced and submitted to GenBank with an accession number KP455483, which had 100% similarity with Homo sapiens leucine rich repeat (in FLII) interacting protein 1 (*LRRFIP1*) transcript variant 5 (NM_001137553.1). *LRRFIP1* cDNA was cloned into the pcDNA3.1 vector (Promega, San Luis Obispo, CA, USA) using restriction enzyme sites of NheI (upstream) and XbaI (downstream).

Hepatoma cells Huh7 and Huh7.5.1 were cultured in DMEM (Dulbecco's modified Eagle medium) supplemented with 10% fetal bovine serum, 1% nonessential amino acids and 1% penicillin/streptomycin (Gibco BRL, Grand Island, NY, USA). Transfection was performed using lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA).

3.2. Antibodies {#sec100528}
---------------

Antibodies used were mouse anti-*LRRFIP1* monoclonal antibody (mAb) (Abcam, Cambridge, MA, USA), rabbit anti-IFN beta mAb (Abcam), mouse anti-HCV NS5A mAb (Virogen, Watertown, MA, USA) and mouse anti-GAPDH mAb (Cell Signaling Technology, Danvers, MA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and goat anti-rabbit IgG were purchased from Invitrogen (Carlsbad, CA, USA).

3.3. Immunofluorescence Assay {#sec100529}
-----------------------------

Huh7 cells were cultured in 96-well plates and fixed for 20 minutes in ice-cold methanol. Cells were then washed with PBS and incubated with PBS containing 3% bovine serum albumin (BSA) for two hours at room temperature. Cells were then incubated with mouse anti-*LRRFIP1* mAb (1:1000) at room temperature. Then cells were washed again and incubated with Alexa Fluor 488 conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA). At last, 4, 6-diamidino-2-phenylindole (DAPI) was used to stain cell nucleus. Cells were finally viewed using Immunofluorescence microscope (Olympus, Japan).

3.4. Cell Proliferation Assay {#sec100530}
-----------------------------

Huh7 cells were cultured in 24-well plates and transfected with plasmids pcDNA-*LRRFIP1* or mock vector. 48 hours after transfection, cells were allowed to grow in 96-well plates (3000 cells/well) and cultured for 24 hours. Cell proliferation was detected using Cell Counting Kit (Transgen, China) at 12 or 24 hours intervals according to the manufacturer's instruction.

3.5. Cell-Culture-Derived HCV (HCVcc) {#sec100531}
-------------------------------------

HCVcc was prepared as previously described ([@A28473R17]).

3.6. Real-Time PCR {#sec100532}
------------------

Total cellular RNA was extracted from cultured cells with TRIzol reagent (Invitrogen), which were reversely transcribed to cDNA using cDNA synthesis kit (Promega, San Luis Obispo, CA). SYBR Premix ExTaq2 (Promega, San Luis Obispo, CA) was used for real-time PCR assay in a StepOnePlus real-time PCR system (Applied Biosystems, CA, USA). Specific primers used for real-time PCR were as follows (5' - 3'): *CTTCACGCAGAAAGCGTCTA* and *CAAGCACCCTATCAGGCA GT* for HCV; *CCAATGGAGAGACTTCCGACA* and *GTCATCTTGGTAGGACCTTGGT* for *LRRFIP1*; *GCTTGGATTCCTACAAAGAAGCA* and *ATAGATGGTCAATGCGGCGTC* for *IFN beta*; TGGGCTACACTGAGCACCAG and AAGTGGTCGTTGAGGGCAAT for *GAPDH*. Data was normalized to *GAPDH* expression in each sample.

3.7. SDS-PAGE and Western Blotting {#sec100533}
----------------------------------

Cells were lysed with Radio Immunoprecipitation Assay Reagent (RIPA) (Beyotime, Jiangsu, China) containing protease and phosphatase inhibitors (Sigma-Aldrich, MO, USA). Protein concentrations in the extracts were measured by BCA Protein Assay Kit (Beyotime, China). Equal amounts of cell lysates were separated on SDS-PAGE gels (12.5%) and then transferred onto PVDF membranes (Bio-Rad, CA, USA). Membranes were blocked with PBS containing 5% nonfat dried milk and 0.1% Tween 20 and incubated at 4°C for 16 hours with monoclonal antibodies to *LRRFIP1*, IFN-β, HCV NS5A and GAPDH, followed by incubation with goat anti-mouse or goat anti-rabbit IgG conjugated with horseradish peroxidase (Invitrogen). Proteins were visualized by the reaction with a chemiluminescent substrate (Thermo Fisher Scientific, Beijing, China).

3.8. Statistical Analyses {#sec100534}
-------------------------

The results were analyzed using SPSS Statistics 18.0 program (IBM, New York, USA). Comparisons between groups were performed using One-way ANOVA and Student's t-test. P values ˂ 0.05 were considered statistically significant.

4. Results {#sec100539}
==========

4.1. LRRFIP1 Promotes IFN-β Expression in Hepatocytes {#sec100536}
-----------------------------------------------------

It has been documented that *LRRFIP1* contributed to the production of IFN-β in macrophages and fibroblast 3T3 cells ([@A28473R14], [@A28473R15]). Therefore, to elucidate the effect of *LRRFIP1* on induction of IFN-β in hepatocytes, *LRRFIP1* was cloned as described in methods section. Hepatoma cells Huh7 were transfected with pcDNA-*LRRFIP1* and mock vector. *LRRFIP1* was over expressed in pcDNA-*LRRFIP1* transfected cells ([Figure 1 A](#fig19249){ref-type="fig"}). We then determined the effect of overexpressed *LRRFIP1* on cell proliferation. As shown in [Figure 1 B](#fig19249){ref-type="fig"}, overexpression of *LRRFIP1* had no impact on Huh7 cell proliferation.

![Effect of LRRFIP1 on Cell Proliferation\
A, Overexpression of LRRFIP1 in Huh7 cells was detected by immunofluorescence assay. B, LRRFIP1 overexpression had no impact on Huh7 cell proliferation.](hepatmon-15-05-28473-i001){#fig19249}

Intracellular IFN-β was detected at 48 hours after transfection in Huh7 and Huh7.5.1 cells transfected with pcDNA-*LRRFIP1*. Results are shown in [Figure 2](#fig19250){ref-type="fig"}. The background transcriptional level of *LRRFIP1* in Huh7 is a little higher than that in Huh7.5.1 cells. The mRNA levels of *LRRFIP1* were extremely increased in pcDNA-*LRRFIP1* transfected Huh7 or Huh7.5.1 cells compared to that in controls ([Figure 2 A](#fig19250){ref-type="fig"}). Overexpression of *LRRFIP1* upregulated the mRNA levels of IFN-β both in Huh7 and Huh7.5.1 cells ([Figure 2 B](#fig19250){ref-type="fig"}). Increased induction of IFN-β in *LRRFIP1* transfected Huh7 and Huh7.5.1 cells were also observed by western blotting ([Figure 2 C](#fig19250){ref-type="fig"}). These data indicate that *LRRFIP1* can drive a type I IFNs response in hepatocytes independently of virus.

![*LRRFIP1* Upregulated the Expression of IFN-β in Huh7 and Huh7.5.1 Cells\
The mRNA levels of *LRRFIP1* (A) and IFN-β (B) were determined by real-time PCR at 24 hours after transfection. Data showed means and standard errors of three replicate assays (\* P \< 0.05, compared with vector). C, Protein levels of LRRFIP1 and IFN-β were quantified by western blotting analyses at 48 hours after transfection.](hepatmon-15-05-28473-i002){#fig19250}

We next analyzed the induction of IFN-β by *LRRFIP1* in the presence of HCV. Huh7 cells were infected with HCVcc at 0.5 multiplicity of infection (MOI) for 12 hours and cells were then transfected with pcDNA-*LRRFIP1* or mock vector. mRNA levels of IFN-β, shown in [Figure 3](#fig19251){ref-type="fig"}, were determined by real time PCR at 48 hours after transfection. The expression of IFN-β was remarkably increased in *LRRFIP1* over-expressed cells with HCV infection suggesting that the induction of IFN-β by *LRRFIP1* was enhanced by HCV infection.

![Induction of IFN-β by *LRRFIP*1 was Enhanced by *HCV* Infection\
Huh7 cells were infected with 0.5 MOI of *HCV*cc. Twelve hours later, cells were transfected with pcDNA-LRRFIP1 or mock vector. mRNA levels of IFN-β were determined by real-time PCR at 48 hours after transfection. Data are shown by means and standard errors of three replicate assays (\* P \< 0.05, compared with control).](hepatmon-15-05-28473-i003){#fig19251}

4.2. Overexpression of LRRFIP1 in Hepatocytes Inhibits HCV Replication {#sec100537}
----------------------------------------------------------------------

IFN-β activates the expression of more than 300 IFN-stimulated genes (ISGs) to execute its antiviral functions. We found that *LRRFIP1* promoted the induction of IFN-β in hepatocytes. To evaluate the anti-HCV activity of *LRRFIP1* in hepatocytes, *LRRFIP1* was transfected into Huh7 cells. Twenty-four hours later, the cells were infected with HCVcc at MOI (multiplicity of infection) of 0.5 and 1. IFN-β and HCV non-structural protein NS5A were determined through western blotting at 48 hours after infection. Results are shown in [Figure 4 A](#fig19252){ref-type="fig"}. IFN-β was upregulated in *LRRFIP1* over-expressed cells with or without HCV infection. Notably, NS5A was decreased in *LRRFIP1* over-expressed cells both in 0.5 MOI and 1 MOI of HCVcc infected cells, which indicates that overexpression of *LRRFIP1* inhibits HCV replication in hepatocytes.

To further evaluate anti-HCV activity of *LRRFIP1*, Huh7 cells cultured in 24-well plates were transfected with pcDNA-*LRRFIP1*. Twenty-four hours after transfection, cells were infected with HCVcc at a MOI of 0.5. HCV RNA levels were determined at 12, 24, 48 and 72 hours post infection. As shown in [Figure 4 B](#fig19252){ref-type="fig"}, HCV RNA levels were lower in *LRRFIP1* overexpressed cells than those in vector control cells at each time points. These data suggest that *LRRFIP1* can inhibit HCV replication in hepatocytes.

![*LRRFIP1* Inhibited *HCV* Infection in Huh7 Cells\
A, Huh7 cells were transfected with LRRFIP1-pcDNA or mock vector. Twenty-four hours after transfection, cells were infected with *HCV*cc. Protein levels of LRRFIP1, IFN-β and *HCV* NS5A were determined by western blotting. B, *HCV* RNA levels were determined by real-time PCR in Huh7 cells transfected with pcDNA-LRRFIP1 or vector control. Data were represented as Means ± SD, n = 3. (\* P \< 0.05, compared with control).](hepatmon-15-05-28473-i004){#fig19252}

4.3. HCV Infection Had Limited Effect on LRRFIP1 Expression in Hepatocytes {#sec100538}
--------------------------------------------------------------------------

The anti-HCV activity of *LRRFIP1* has been identified above. Therefore, we wish to further define whether HCV infection regulates the expression of *LRRFIP1* in hepatocytes. Huh7 cells were infected with 0.5 MOI of HCVcc and *LRRFIP1* levels were determined at different time points post infection by real-time PCR and western blotting.

As shown in [Figure 5A](#fig19253){ref-type="fig"} and [5B](#fig19253){ref-type="fig"}, HCV replicated in Huh7 cells and had a peak value at 4 days post infection, while the mRNA and protein levels of *LRRFIP1* were similar before and after HCV infection. To further explore the effect of HCV infection on *LRRFIP1* expression, Huh7 cells were infected with different doses of HCVcc. Seventy-two hours later, the intracellular mRNA and protein levels of *LRRFIP1* were determined. Similarly, no change expression of LRFFIP1 was observed in HCV infected Huh7 cells ([Figure 5 C](#fig19253){ref-type="fig"} and [5D](#fig19253){ref-type="fig"}). Similar results were also observed in Huh7.5.1 cells (data not shown). These results suggest that HCV infection had limited effect on *LRRFIP1* expression in hepatocytes.

![Effect of *HCV* Infection on Expression of *LRRFIP1* in Huh7 Cells\
mRNA levels (A) and protein levels (B) of *LRRFIP1* and *HCV* were detected at different time points post infection. mRNA levels (C) and protein levels (D) of LRRFIP1 and *HCV* were detected in Huh7 cells infected with different doses of *HCV*cc. Data were presented by Means ± SD, n = 3.](hepatmon-15-05-28473-i005){#fig19253}

5. Discussion {#sec100540}
=============

Type I interferon (IFN-α/β) is induced in cells immediately after virus infection; therefore, is the first line of defense that inhibits virus replication and infection ([@A28473R18]). The signaling pathways of virus-triggered type I IFNs have been clarified by a large number of researches. It is well known that cytoplasmic helicase proteins such as RIG-I and MDA5 sense the presence of viruses and activate adaptor proteins, which mediates the signal to downstream factors and finally inducing the expression of type I IFNs ([@A28473R19], [@A28473R20]).

Despite the advances of findings in signaling pathways of virus-triggered type I IFNs, new mechanisms of virus induction of IFNs have been discovered. *LRRFIP1* is recently found as cytosolic nucleic acid-binding protein, which bound exogenous nucleic acids and increased the expression of IFN-β in macrophages and fibroblasts cells ([@A28473R14], [@A28473R15]). *LRRFIP1* is primarily found as a protein, which interacts with leucine rich repeat of flightless I. Suriano et al. reported that *LRRFIP1* is able to suppress the expression of tumor necrosis factor α (TNF-α) ([@A28473R21]). *LRRFIP1*, localized mainly in the cytoplasm, is able to directly bind to viral dsRNA and induce the expression of type I IFNs ([@A28473R12], [@A28473R21]). Therefore, *LRRFIP1* is a potent activator of innate immune responses in mammalian cells that is important for pathogen elimination.

In this study, we showed that *LRRFIP1* contributed to HCV-induced production of IFN-β in hepatocytes. Overexpression of *LRRFIP1* upregulated the mRNA and protein levels of IFN-β in Huh7 and Huh7.5.1 cells. Moreover, induction of IFN-β by *LRRFIP1* is independent of HCV infection.

Previous studies clarified the signaling chain activated by viral RNA in infected cells. Several studies showed that two intracellular RNA helicases, RIG-I and MDA5, act as sentinels for viral RNA ([@A28473R19], [@A28473R20]). Then several adaptor proteins such as Cardif (CARD adaptor inducing IFN-β) and IPS-1 (interferon-β-promoter stimulator 1) were activated and mediated the signal to two IκB kinase (IKK)-related kinases, which then phosphorylate the transcription factor IRF-3 ([@A28473R22]). Phosphorylated IRF-3 moves into the nucleus and initiates transcription of genes encoding type I interferons ([@A28473R23]).

However, the exact molecular pathway of *LRRFIP1* induced IFN-β is still not clear. Studies showed that *LRRFIP1* bound and activated β-catenin. The activated β-catenin subsequently bound IRF3, which resulted in the transcription of type I interferons as the regular pathway ([@A28473R15]). While Bagashev et al. found that *LRRFIP1* sensed early endosomes containing RNA of influenza virus in fibroblasts 3T3 cells. It is possible that *LRRFIP1* serves as a bridge for the TLR3 signal pathway ([@A28473R14]). The mitogen-activated protein kinases p38 appears to actively regulate *LRRFIP1* recruitment to the endosome in this process. However, knockdown of *LRRFIP1* did not affect the phosphorylation of p38 ([@A28473R15]). Therefore, the exact pathway of *LRRFIP1* inducing type I interferons needs further researches.

We identified that *LRRFIP1* can induce IFN-β in hepatocytes with or without HCV infection. Induction of IFN-β was enhanced by the presence of HCV. In addition, induction of IFN-β was observed both in Huh7 and Huh7.5.1 cells. The clone Huh7.5.1 of human hepatoma cells contains a mutation in RIG-I, while Huh7 cell has intact RIG-I expression. Therefore, Huh7 cells respond to HCV and induce the transcription of IFNs, while Huh7.5.1 cells induce extremely low levels of IFNs due to containing a mutation in RIG-I. Induction of IFN-β by overexpression of *LRRFIP1* was identified both in Huh7 and Huh7.5.1 cells, which indicates that RIG-I mutation does not affect the induction of IFN-β by *LRRFIP1*. Thus, induction of IFN-β by *LRRFIP1* is probably not through RIG-I related pathway.

In addition, Nguyen JB and Modis Y reported a crystal structure of the dimeric coiled-coil domain of *LRRFIP1* ([@A28473R13]). *LRRFIP1* contains an N-terminal domain of unknown function (aa 1 - 162), a conserved 87-amino acid domain predicted to be a coiled coil (aa 163-249) and a nucleic acid binding domain (aa 250 - 808). C-terminal DNA-binding domain (*LRRFIP1*-DBD, aa 250 - 808) alone is mostly unfolded and has very little secondary structure. In the context of the coiled coil domain, *LRRFIP1*-CC-DBD (aa 163 - 808) was also unfolded, but was mostly oligomeric. Although *LRRFIP1*-DBD can bind with DNA, it still lacks secondary structure, while *LRRFIP1*-CC-DBD can assemble into higher order oligomers in the context of binding with DNA. Moreover, the coiled coil domain is found in all LRRFIP isoform genes and is highly conserved, which indicates its important role. Thus it is interesting to address whether *LRRFIP1*-DBD or in the context of the coiled coil domain can induce the transcription of Type 1 IFNs. This would be detected in further studies.

In summary, our findings revealed a role for *LRRFIP1* in controlling HCV infection. We identified that *LRRFIP1* implicated in the innate responses to HCV in liver cells. Although HCV infection did not regulate the expression of *LRRFIP1*, over-expressed *LRRFIP1* in Huh7 and Huh7.5.1 cells inhibit HCV replication. It is an alternative method for antiviral management to mediate the expression of *LRRFIP1*, which provides new target for HCV treatment and contributes to the development of anti-HCV drugs. Further researches are needed to clarify delicate regulatory mechanisms of *LRRFIP1* in inducing type I interferons and its role of antiviral responses. Moreover, factors that mediate the expression of *LRRFIP1* should be investigated.
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